How Much Did Atomwise Raise? Funding & Key Investors

Atomwise has successfully raised $174 million over multiple funding rounds, with its latest being a Series C. The company leverages artificial intelligence to revolutionize drug discovery, attracting significant interest from investors.

Keep reading to explore the intricacies of Atomwise's fundraising journey and the investors backing this innovative platform.

What Is Atomwise?

Founded in 2012, Atomwise is based in San Francisco, California. The company specializes in using artificial intelligence to revolutionize drug discovery.

Atomwise was co-founded by Abraham Heifets, Alex Levy, and Izhar Wallach. Their innovative approach leverages deep learning algorithms and supercomputers to develop new medicines.

With a team of 51-100 employees, Atomwise continues to push the boundaries of what's possible in the pharmaceutical industry.

How Much Funding Has Atomwise Raised?

1. Pre-Seed Round
   • Amount Raised: $120K
   • Date: March 2015
   • Lead Investors: Not publicly disclosed
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To kickstart the development of their AI-driven drug discovery platform.
2. Seed Round
   • Amount Raised: $6M
   • Date: June 2015
   • Lead Investors: Not publicly disclosed
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To further develop their technology and expand their team.
3. Series A
   • Amount Raised: $45M
   • Date: March 2018
   • Lead Investors: Monsanto Growth Ventures (MGV)
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To scale their AI technology and increase research collaborations.
4. Series B
   • Amount Raised: $123M
   • Date: August 2020
   • Lead Investors: B Capital, Sanabil
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To scale technology, team, and operations, and to expand joint ventures.
5. Grant
   • Amount Raised: $2.3M
   • Date: October 2020
   • Lead Investors: Bill & Melinda Gates Foundation
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To support specific research initiatives and collaborations.
6. Series C
   • Amount Raised: $45M
   • Date: January 2024
   • Lead Investors: Not publicly disclosed
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To continue scaling their AI technology and expand their market reach.

Total Amount Raised: $221.7M. Current Valuation: Not publicly disclosed.

Key Investors

• Bill & Melinda Gates Foundation
  • Details: A private foundation founded by Bill and Melinda Gates, focusing on global health, education, and poverty alleviation.
  • Investment Focus Areas: Global health, education, poverty alleviation.
  • Notable Investments: Gavi, the Vaccine Alliance, Global Polio Eradication Initiative, PATH.
• B Capital Group
  • Details: A venture capital firm co-founded by Eduardo Saverin and Raj Ganguly, focusing on innovative companies in various sectors.
  • Investment Focus Areas: Healthcare, technology, innovation.
  • Notable Investments: Evidation Health, Icertis, Ninja Van.
• Sanabil Investments
  • Details: A Saudi Arabian investment firm that provides growth capital to innovative companies across various sectors.
  • Investment Focus Areas: Technology, healthcare, financial services.
  • Notable Investments: Magic Leap, Uber, Noon.
• DCVC (Data Collective)
  • Details: A venture capital firm that invests in deep tech companies, particularly those leveraging AI and machine learning.
  • Investment Focus Areas: AI, machine learning, biotechnology.
  • Notable Investments: Zymergen, Planet Labs, Pivot Bio.
• Tencent
  • Details: A Chinese multinational conglomerate holding company, known for its investments in internet-related services and products, entertainment, AI, and technology.
  • Investment Focus Areas: Technology, internet services, healthcare.
  • Notable Investments: Epic Games, Tesla, JD.com.

What's Next for Atomwise?

Atomwise stands at the cusp of a transformative era in drug discovery. With opportunities to develop and commercialize small molecule therapies, the company is poised to capture significant value by expanding partnerships with both large pharmaceutical companies and smaller biotech firms. The market potential is immense, estimated to be four times the value of the entire pharma industry today.

Future fundraising efforts will likely focus on scaling their technology and team, supported by continued investment from existing and new investors. However, challenges such as ensuring the precision and safety of new therapies, navigating regulatory requirements, and managing the complexity of scaling operations remain. As Atomwise continues to innovate, the path ahead promises both significant opportunities and hurdles.

Use Clay to Get Funding Data

Sales professionals, take your strategy to the next level by leveraging Clay's platform to access comprehensive fundraising data on companies like Atomwise and gather other critical business insights.

Sign up for free on Clay and start making data-driven decisions today.